Fasler Katrin, Gunzinger Jeanne M, Barthelmes Daniel, Zweifel Sandrine A
Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland.
University of Zurich, Zurich, Switzerland.
Front Pharmacol. 2021 May 10;12:675295. doi: 10.3389/fphar.2021.675295. eCollection 2021.
To evaluate efficacy of eplerenone therapy vs. observation on resolution of subretinal fluid (SRF) in patients with acute and chronic central serous chorioretinopathy (CSCR) in routine clinical practice. Retrospective comparative case series of eyes diagnosed with CSCR treated with eplerenone or observation. Primary outcome measure was maximum height of SRF at 12 months. Secondary outcome was percentage of eyes with complete resolution of SRF, percentage of eyes with reduction of SRF ≥50%, and best corrected visual acuity (VA) at 12 months. Separate analysis was conducted for eyes with acute and chronic CSCR. Sixty-eight eyes of 60 patients (82% male) were included. Eleven of the 38 eyes with acute CSCR, and seven of the 30 eyes with chronic CSCR, received eplerenone. Subretinal fluid decreased from baseline to 12 months in acute (287 ± 221 to 31 ± 63 µm) and chronic (148 ± 134 to 40 ± 42 µm) CSCR. Kaplan-Meier curves were similar for treated and observed eyes and COX regression analysis did not show a significant difference in SRF resolution in treated vs. observed eyes (p = 0.6 for acute, p = 0.2 for chronic CSCR). This routine clinical practice outcome study did not show evidence of efficacy of eplerenone on resolution of SRF in acute nor chronic CSCR.
在常规临床实践中，评估依普利酮治疗与观察对急性和慢性中心性浆液性脉络膜视网膜病变（CSCR）患者视网膜下液（SRF）消退的疗效。对诊断为CSCR并接受依普利酮治疗或观察的眼睛进行回顾性比较病例系列研究。主要结局指标是12个月时SRF的最大高度。次要结局是SRF完全消退的眼睛百分比、SRF减少≥50%的眼睛百分比以及12个月时的最佳矫正视力（VA）。对急性和慢性CSCR的眼睛进行了单独分析。纳入了60例患者的68只眼睛（82%为男性）。38只急性CSCR眼睛中的11只，以及30只慢性CSCR眼睛中的7只，接受了依普利酮治疗。急性CSCR（从287±221至31±63µm）和慢性CSCR（从148±134至40±42µm）的视网膜下液从基线到12个月均有所下降。治疗组和观察组眼睛的Kaplan-Meier曲线相似，COX回归分析显示治疗组与观察组眼睛在SRF消退方面无显著差异（急性CSCR，p = 0.6；慢性CSCR，p = 0.2）。这项常规临床实践结局研究未显示依普利酮对急性或慢性CSCR的SRF消退有效。
